Pharmaceutical

Fulcrum and CAMP4 to develop rare blood disorder therapies

Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.

Jul 11, 2023 - 20:00
Fulcrum and CAMP4 to develop rare blood disorder therapies
Fulcrum Therapeutics has signed a licence agreement with CAMP4 Therapeutics to develop new therapies to treat Diamond-Blackfan anaemia.
Read the original article

Tags:

Previous Article

Iovance looks to advance its non-small cell lung cancer therapy

Next Article

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves new administration routes for Xcopri 

FDA approves new administration routes for Xcopri 

Apr 13, 2024

STAT+: Merck, Johnson & Johnson CEOs agree to testify in Congress on high drug prices, avoiding Bernie Sanders’ subpoena

STAT+: Merck, Johnson & Johnson CEOs agree to testify i...

Jan 26, 2024

Kinnate Biopharma announces 70% layoffs and pipeline restructuring

Kinnate Biopharma announces 70% layoffs and pipeline re...

Sep 19, 2023